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Abstract
Background: Generalised anxiety disorder (GAD) is a high prevalence, chronic psychiatric disorder which commonly 
presents early in the lifespan. Internet e-health applications have been found to be successful in reducing symptoms of 
anxiety and stress for post traumatic stress disorder (PTSD), panic disorder, social phobia and depression. However, to 
date, there is little evidence for the effectiveness of e-health applications in adult GAD. There are no studies which have 
directly compared e-health applications with recognised evidence-based medication. This study aims to determine 
the effectiveness of a web-based program for treating GAD relative to sertraline and attention placebo.
Methods/Design: 120 community-dwelling participants, aged 18-30 years with a clinical diagnosis of GAD will be 
recruited from the Australian Electoral Roll. They will be randomly allocated to one of three conditions: (i) an online 
treatment program for GAD, E-couch (ii) pharmacological treatment with a selective serotonin re-uptake inhibitor 
(SSRI), sertraline (a fixed-flexible dose of 25-100 mg/day) or (iii) an attention control placebo, HealthWatch. The 
treatment program will be completed over a 10 week period with a 12 month follow-up.
Discussion: As of February 2010, there were no registered trials evaluating the effectiveness of an e-health application 
for GAD for young adults. Similarly to date, this will be the first trial to compare an e-health intervention with a 
pharmacological treatment.
Trial Registration: Current Controlled Trials ISRCTN76298775
Background
Generalised anxiety disorder is a high prevalence psychi-
atric disorder that is associated with low rates of treat-
ment. The predominant symptom of GAD is excessive
uncontrollable worry in a variety of domains that lasts for
a period of at least six months. Associated symptoms
include muscle tension, becoming fatigued easily, rest-
lessness, irritability, and sleep disturbance [1]. Lifetime
and 12 month prevalence rates have been estimated at
between 4.3-5.9% and 1.2-1.9% respectively [2,3]. How-
ever, a relatively small percentage of those with GAD seek
treatment. Findings from the US National Comorbidity
Survey indicated that only 37% of respondents had
sought treatment for the disorder [4].
The condition generally follows a chronic course, with
symptoms often presenting early in the lifespan and
affecting individuals throughout adulthood. There is an
estimated delay of treatment following the initial onset of
symptoms for the affected individual of between 9 and 23
years [5]. Consequently, the community cost associated
with GAD is high [6]. Effective treatment in young adult-
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hood has the potential to reduce ongoing disability and
costs [7,8]. Young adults (18-30 years) will be the target of
the current study, allowing the effects of treatment to be
investigated in the age group when GAD commonly first
presents.
Current Psychological and Pharmacological Treatments for 
GAD
Both cognitive behavioural therapy (CBT) and drug treat-
ments such as selective serotonin reuptake inhibitors
(SSRIs) are commonly used to treat GAD [9]. Meta-anal-
yses suggest CBT is an effective treatment for GAD,
reducing anxiety and worry in the short- and long-term
[10,11]. Sertraline, along with the SSRIs escitalopram and
paroxetine, is seen as a first-line pharmacologic treatment
for GAD [12]. Randomised, placebo controlled trials have
found sertraline efficacious for GAD in adults [13,14],
children and adolescents [15,16]. The treatment period
ranged from 9 to 12 weeks in these pharmacological tri-
als. A review of antidepressant medication concluded ser-
traline (along with escitalopram) has the most favourable
balance between efficacy, acceptability (side effects and
treatment discontinuation) and acquisition cost. Consid-
ering these findings, sertraline is a standard choice for
treating GAD in clinical settings. While both CBT and
SSRIs are beneficial, some evidence suggests that the
effects of CBT may be more long lasting [10,17].
Despite the benefits of CBT and SSRIs, many individu-
als either do not or are not able to access treatment. This
is particularly the case for those seeking CBT, which is
difficult to obtain due to the small workforce of psycholo-
gists and the lack of services in rural and remote regions
[18]. Further, there is evidence that many individuals with
mental health problems seek confidential services where
anonymity is assured [19]. E-health applications provid-
ing CBT for anxiety are a potential solution to poor
access to services. Considering the preference for confi-
dentiality and anonymity, the low workforce required for
dissemination and the lack of intense input needed from
mental health professionals, automated e-health pro-
grams offer potential for intervention en masse.
In the last 10 years, hundreds of e-health applications
have been developed. Many have been found to be effec-
tive, although the effectiveness of these applications for
GAD is not well established relative to applications for
other anxiety disorders (see Spence et al [20]) including
social anxiety [21], panic disorder [22,23] and PTSD [24],
and for depression [25,26], stress [19], insomnia [27] and
eating disorders [28] (see http://www.bea-
con.anu.edu.au[29] for a list of all research). A prelimi-
nary case study of an internet self-management program
for GAD indicated the promise of such an intervention,
with clinically significant improvements found on mea-
sures of GAD symptomatology, worry and metacogni-
tions [30]. Recently, the first randomised controlled trial
(RCT) of an Internet-based CBT program for GAD was
completed with results suggesting the Internet-based
program, compared to a waitlist control, resulted in clini-
cally significant reductions in worry and symptoms of
anxiety. Efficacy and completion rates were similar to
those seen for traditional face-to-face CBT programs
[31]. Given the likely importance of these applications in
the future, particularly for high prevalence disorders such
as GAD, it is important to evaluate their effectiveness rel-
ative to gold standard pharmacological treatment and
also against a credible attention placebo control [10,17].
Objectives of the Current Study
The primary aims of this study are to investigate in indi-
viduals with a GAD diagnosis, whether an e-health appli-
cation (E-couch) (i) is more effective than an attention
placebo health application (HealthWatch) in reducing
symptoms of anxiety and in lowering the proportion of
the sample with a GAD diagnosis, and (ii) produces an
equivalent reduction in symptoms compared to the use of
the SSRI, sertraline. A secondary aim of the study is to
investigate participant characteristics that predict out-




The study is a randomised controlled trial of community
dwelling young adults. It will consist of a 10 week treat-
ment phase and a 12 month follow-up phase, with mea-
sures administered at screening, baseline, post-test, and 6
and 12 months after post-test. The current study has
received ethics approval from The University of Sydney
(11-2009/12091) and The Australian National University
(2008/548) Human Research Ethics Committees and
complies with the Helsinki Declaration on human
research.
Participants and Inclusion/Exclusion Criteria
The target population for the GAD treatment trial is
adults, male and female, aged 18-30 years with an anxiety
diagnosis of GAD. The study aims to recruit 120 partici-
pants (40 per condition).
Individuals screened positive for GAD symptoms but
not found to meet GAD diagnosis using the Mini-Inter-
national Neuropsychiatric Interview (MINI) [32] will be
invited to join a parallel GAD prevention RCT [33].
The eligibility criteria for the GAD treatment trial are
listed in Table 1.
As there is considerable comorbidity between GAD,
other anxiety disorders and depression [34], a secondary
diagnosis of an anxiety disorder or major depression is
not an exclusion criterion of this study. However, if par-Christensen et al. Trials 2010, 11:48
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ticipants are found to have a primary diagnosis of one of
these conditions, with GAD a secondary diagnosis they
will be excluded from the study and offered more appro-
priate treatment options. These diagnoses will be based
on Anxiety Disorders Interview Schedule-IV (ADIS-IV)
[35] criteria.
Recruitment Procedure
Recruitment will take place in three stages. Stage 1 will
involve a screening assessment, mailed to individuals in
five Sydney electorates who are randomly selected from
the Australian Electoral Roll. In Australia it is compulsory
for all Australian citizens aged 18 years or older to be reg-
istered on the Commonwealth Electoral Roll. Return of
the screener will constitute consent to participate in this
stage. Randomly selected individuals will be screened for
symptoms using the GAD-7 [36]. Stage 2 will involve the
a d m i n i s t r a t i o n  o f  t h e  M I N I  b y  t e l e p h o n e  ( a f t e r  v e r b a l
informed consent) to individuals with a GAD-7 score of 5
or more. Individuals who meet criteria for GAD on the
MINI interview will be offered a referral to the treatment
trial at the Brain & Mind Research Institute (BMRI), The
University of Sydney. Stage 3, which will take place at the
Brain & Mind Research Institute, will involve the admin-
istration of questionnaires and the ADIS-IV, a structured
clinical interview, to determine a clinical diagnosis of
GAD. Participants will also undertake a medical consul-
tation with a general practitioner (GP) to ascertain suit-
ability to be prescribed sertraline. Written informed
consent will be obtained to participate in the trial before
the assessment begins.
Baseline and Randomisation
Once consent has been obtained and participants are
deemed eligible to enter the trial, they will be sent an
email asking them to complete the baseline questionnaire
online. Randomisation to one of three treatment condi-
tions will occur immediately after the baseline has been
completed using existing web-based software developed
by the investigators. Randomisation will occur in random
block sizes of three, six and nine with stratification for
gender and secondary diagnosis of depression. Partici-
pants will be informed of their allocation when returning
to the web portal after completing the questionnaire.
Random allocation will be carried out by automated algo-
rithms within the e-health system. In accordance with
ICH Guideline E9 [37], staff responsible for establishing
randomisation procedures will not be involved in the
day-to-day conduct of the trial. Further, no staff members
involved in the day-to-day running of the trial (who will
not be blind to group membership) will be involved in
conducting follow-up assessments. Research staff will not
Table 1: Inclusion/exclusion criteria for the GAD treatment trial
Inclusion Criteria Exclusion Criteria
18-30 years old Currently undertaking CBT with psychologist health care professional
Primary diagnosis of GAD (based on ADIS-
IV criteria)
Currently seeing a psychologist or psychiatrist
Consent to participate in the trial Taking psychotropic drugs
Access to the Internet At risk of self-harm or suicide
Active email address and phone number Current or past diagnosis of psychosis, schizophrenia or bipolar disorder
Sufficient English language literacy Current primary diagnosis of major depressive disorder, panic disorder, social phobia, 
obsessive compulsive disorder, post-traumatic stress disorder or substance dependence (i.e. 
a comorbid disorder deemed to require treatment before GAD). This will be ascertained by 
administering the ADIS-IV and establishing primary and secondary diagnoses.
Treatment with Monoamine Oxidase Inhibitors (+/- 14 days before or after treatment) or 
concomitant pimozide
Treatment with sertraline in the past three months for a period of two or more weeks
Planning to become pregnant, pregnant or breastfeedingChristensen et al. Trials 2010, 11:48
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be aware of group membership during the baseline
assessments as randomisation occurs after this stage.
Online Programs
E-couch Website
The study version of the E-couch website is divided into
10 modules, completed over the 10 week intervention
period. E-couch comprises four sections including psy-
choeducation, cognitive behaviour therapy, relaxation
and physical activity. The psychoeducation section (mod-
ules 1 and 2) includes information on worry and how it is
distinct from stress; fear and anxiety; a description of
anxious thinking; differentiation of GAD from other anx-
iety disorders; risk factors for GAD; comorbidity; conse-
quences of anxiety and available treatments. This section
is based on interventions for mental health literacy that
have reduced symptoms of depression and anxiety, and
improved mental health attitudes [38]. The CBT toolkits
(modules 3-7) address typical anxious thoughts and
include sections on dealing with the purpose and mean-
ing of worry, the act of worrying and the content of
worry. The information is derived from materials which
have been found to reduce anxious cognitions in at-risk
people [39,40]. Relaxation techniques will be covered in
modules 8 and 9. The progressive muscle relaxation
(PMR) module instructs participants how to progres-
sively tense and relax different muscle groups to induce
relaxation and help individuals identify tension early.
PMR has been trialled in a previous website program for
depression in adults [41] and adolescents [42]. The mind-
fulness meditation module helps participants become
aware of their breathing and body, acknowledging
thoughts and external distractions but remaining focused
on the present. The final module, physical activity, tailors
advice about physical activity based on the stages of
change theory [43].
HealthWatch Website
HealthWatch is an online program developed for the
ANU WellBeing study [44]. As implemented in the cur-
rent study, the program will provide information about
various health topics each week for 10 weeks. These
cover environmental health, nutrition myths, heart
health, activity, medication, the effects of temperature,
oral health, blood pressure and cholesterol, calcium, and
back pain. Participants are also asked to respond to a
number of questions about potential risk factors for anxi-
ety. Preliminary data from the ongoing WellBeing trial
suggests that HealthWatch is not associated with a reduc-
tion in anxiety or depressive symptoms over time. If evi-
dence suggests E-couch is an effective treatment for
GAD, all participants in the HealthWatch (and SSRI med-
ication) condition will be offered access to E-couch at the
end of the 12 month follow-up. During the 12 month fol-
low-up period, participants in this condition will have the
option of receiving treatment (therapy or pharmacologi-
cal) at the Brain & Mind Research Institute Clinical Cen-
tre or seeking a referral to an appropriate health
professional.
Participant's time on the E-couch or HealthWatch web-
site, number of modules completed, length of individual
module use and frequency of access will be recorded
automatically using website software.
Components of Trial Conditions during Intervention Phase
All participants, regardless of condition, will be provided
with the same amount of exposure to the clinical team of
psychologists and GPs. Specifically, all trial participants
will have an appointment with a psychologist in weeks 1,
2, 5 and 10 to monitor progress and symptoms, and each
will be reviewed by a GP in weeks 1, 5 and 10 to match
the required assessments for those in the SSRI medica-
tion condition. These review sessions across conditions
ensure matching for clinician/GP involvement across
interventions. The Clinical Global Impressions scale
(CGI) [45] will be administered on each of these occa-
sions to gauge treatment response. The specific content
of the program conditions are outlined below.
Online Program Conditions
Participants will complete the 10 week E-couch or
HealthWatch online program at their home or office.
Modules last between 30 and 60 minutes and will be
deployed weekly. During monitoring sessions in weeks 1,
2, 5 and 10, the psychologist will encourage use of the
website but will not elaborate on CBT techniques. If par-
ticipants in the E-couch condition wish to continue using
the program after the 10 week intervention period, they
have the option of accessing it through the open-access
website.
SSRI Medication Condition
Participants are prescribed sertraline for 10 weeks by a
GP at the Brain & Mind Research Institute. Sertraline
treatment will be initiated at a daily dose of 25 mg which
will increase to 50 mg/day after one week provided par-
ticipants display good tolerability. Thus, if participants
report side effects during the first week of sertraline
treatment and the GP deems they should remain on the
lowest dose, they will continue on 25 mg/day until further
assessment. Individuals experiencing side effects can be
seen at additional medical appointments at any point
throughout the trial if necessary.
After four weeks at a daily dose of 50 mg, participants
with insufficient clinical response but good tolerability
(i.e. no significant side effects) will be permitted to
increase to a maximum of 100 mg/day. Sufficient clinical
response will be defined as a CGI-Global Improvement
score of 1 (Very much improved) or 2 (Much improved).
To monitor for any additional or augmented side effects
which may result due to this increased dosage, psycholo-Christensen et al. Trials 2010, 11:48
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gists will telephone all trial participants during week 6 (to
match for clinician contact), with additional GP appoint-
ments arranged if necessary.
If participants experience side effects that are distress-
ing, or their nature and/or severity are not consistent
with existing Product Information, they may be with-
drawn from the trial and offered alternative treatment.
At the end of the 10 week intervention period if partici-
pants have responded to treatment, they will have the
option of continuing sertraline (either under the care of
GPs at the Brain & Mind Research Institute or their own
GP).
Primary Outcome Measures
The primary outcome measures will be level of anxiety
symptoms as indexed by scale scores on the GAD-7 [36]
(a continuous measure), the achievement of a reduction
of at least 20% on this scale (a binary score) and presence
or absence of GAD diagnoses based on the ADIS-IV.
Secondary Outcome Measures
A range of secondary outcomes will be investigated.
Reduction in worry will be measured by the Penn State
Worry Questionnaire (PSWQ) [46] and the Anxious
Thoughts Inventory (AnTI) [47]; reduced impact of
worry and anxiety on participants' lives by the Life Inter-
ference Scale (LIS); reduction of somatic symptoms asso-
ciated with GAD by the somatic subscale of the W orry
and Anxiety Questionnaire (WAQ-Som) [48] and reduc-
tion in anxiety sensitivity assessed by the Anxiety Sensi-
tivity Index (ASI) [49]. Reductions in depression
symptoms will be measured by the Centre for Epidemio-
logical Studies-Depression scale (CES-D) [50] and the
Patient Health Questionnaire- Depression [51]; level of
psychosocial distress by the Kessler-10 (K-10) [52] and
Depression, Anxiety Stress Scale-21 (DASS-21) [53];
reductions in the level of harmful/hazardous alcohol use
will be assessed by the Alcohol Use Disorders Identifica-
tion Test (AUDIT) [54] and reduced disability measured
by the 'Days out of Role' questions from the US National
Comorbidity Survey [55]. Psychologists' ratings of
response to treatment will be assessed using the Clinical
Global Impression rating scale (CGI) [45].
Improvements in health knowledge will be assessed
using the Anxiety Literacy Scale (A-Lit) [26], a format
previously developed for depression and adapted for anx-
iety. Outcome measures will be included to assess poten-
tial risk factors and predictors of treatment response.
Stigma toward people with GAD (both personal and per-
ceived) will be measured by a recently developed scale,
the Generalised Anxiety Stigma Scale (GASS), which uses
a format previously developed for depression [26] and
which is currently being validated in a separate study.
Perceptions of personal health will be rated by a self-per-
ceived emotional health item, and individuals' ability to
identify mental illness in themselves will be assessed
using prototypes (i.e., how alike to three people whose
symptoms profiles are described does the participant rate
themselves) (in development). Symptoms of social phobia
will be assessed using the Social Phobia Inventory (SPIN)
[56] and a new social phobia screener that is in develop-
ment, and panic disorder symptoms will be assessed by
the Patient Health Questionnaire- Panic [51] and a new
panic disorder screener, also in development. Availability
of social support will be evaluated by the Medical Out-
comes Study- Social support survey [57] and adherence
will be assessed by website usage and pill counts.
Predictors including childhood adversity, life events
and physical health will use scales previously developed
for the Personality and Total Health (PATH) Through
Life project [58]. Additional predictor variables will
include perceived helpfulness of treatment sources, med-
ication use, alcohol use and smoking.
Subsidiary Outcome Measures
A  n u m b e r  o f  s u b s i d i a r y  o u t c o m e s  w i l l  b e  m e a s u r e d ,
including direct costs of each condition, and satisfaction
with treatment employing previously used self-report
scales. Additionally, the demographic data will be analy-
sed to compare those who responded with the general
population.
Power
The GAD treatment trial aims to recruit 120 participants
(40 per group). Most CBT-based treatment trials of GAD
report an effect of approximately .6 SDs relative to a pla-
cebo and 0.8 SDs relative to minimal contact. Pharmaco-
logical treatments of GAD report an effect of
approximately 0.3 SDs compared to placebo. Based on the
primary outcome measure of differences in anxiety scale
s c o r e s  o n  t h e  G A D - 7 ,  t h i s  s a m p l e  s i z e  w i l l  h a v e  8 0 %
power to detect a moderate effect size. Assuming a corre-
lation of .7 between pre- and post-test measures, the
study will have 80% power to detect differences in change
from baseline of approximately. 3SDs in a priori contrasts
of trial conditions conducted within the framework of an
omnibus test.
Statistical Analyses
To ensure the statistical analysis is masked, the senior
trial biostatistician will be blinded to treatment group
status until the analysis has been completed. Further, no
trial biostatisticians will be involved in the administration
of treatment, measurement of outcomes, data entry or
assessment of participant eligibility. All researchers con-
ducting the ADIS-IV assessments will be blind to treat-
ment group status. Randomisation will take place after
the baseline ADIS-IV and researchers conducting the fol-Christensen et al. Trials 2010, 11:48
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low-up assessments will have no involvement in the
administration of treatment. The success of blinding will
be evaluated by asking assessors to guess which treat-
ments the participants they rated had received. Surveys
completed online are effectively blind. The trial manager,
and clinicians and GPs conducting the monitoring ses-
sions will need to be aware of participants' group mem-
bership (to discuss progress with the respective programs
and alter medication dosages in line with the protocol).
Participants in the online groups will be unaware as to
whether their program is an active treatment or control.
Primary effectiveness analyses will be undertaken on an
intention-to-treat basis. Any participants who were ran-
domised but withdraw from the study, or who take up
alternative treatments, will be included in the analysis as
randomised. Mixed-model repeated measures analysis
will be used to compare outcome over time across the
groups. This analysis will be utilised because of its ability
to include participants with missing data. If necessary,
multiple imputation using demographic and other back-
ground variables as predictors may be used to allow
inclusion of data from all participants. Comparison of
online therapy to sertraline will be undertaken within a
non-inferiority/equivalence framework with the non-
inferiority margin chosen post hoc to ensure a significant
outcome. Appropriate approaches to analysis will be
used, recognising that intention-to-treat may lead to an
underestimate of differences between treatments [59].
Relative risk will be calculated and tested for signifi-
cance for categorical outcomes (achieving a 20% reduc-
tion in symptoms and the absence of DSM-IV GAD
diagnoses). These outcomes will also be expressed in
terms of number needed to treat.
Additional analyses will explore participant character-
istics which moderate outcome and, if appropriate, levels
o f  p r e s e n t i n g  s e v e r i t y  a s s o c i a t e d  w i t h  s i g n i f i c a n t
improvement. Other outcomes (e.g., reasons for drop-
out) will be described.
Discussion
As of February 2010, there were no registered ran-
domised controlled trials examining the effectiveness of
online CBT treatments for GAD in young adults. This
trial will be one of the first to assess the use of an inter-
net-based CBT program in the treatment of GAD, and to
date, the first to compare it with a gold standard pharma-
cological treatment.
This trial also attempts to address a number of method-
ological limitations that have been identified in previous
internet-based treatment trials, by incorporating a longer
follow-up period of 12 months, documenting randomisa-
tion procedures, controlling for the amount of contact
received by participants in each of the conditions,
analysing predictors of treatment response and adher-
ence and including cost-effectiveness data [60]. By com-
paring the findings to the standard first line treatment
offered in general practice, the outcomes of the present
trial are highly relevant to the practical management of
GAD in primary care. If GAD treatment using an e-
health application with minimal therapist input proves to
be effective, it offers an attractive alternative to medica-
tion and may be a preferred treatment in the first stage of
a stepped care intervention. Given the shortage of quali-
fied therapists, escalating health costs and the low rates of
treatment seeking in those with a mental disorder [4], this
trial has important clinical and practical outcomes.
Status of the Trial
The study commenced in May 2010. To allow adequate
time to implement the intervention, participants will be
recruited in four intake cohorts approximately 2-3
months apart. The trial is expected to end in May 2012.
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